Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer

Fasting insulin is related to outcome in early breast cancer. We evaluated the expression of insulin receptor (IR) and its prognostic significance in patients with early stage breast cancer. Tumors from 191 patients with T1-3, N0-1, M0 breast cancer who were enrolled at a single center of a multicenter cohort study were used to construct microarrays with subsequent immunohistochemical evaluation of IR, IGF-IR, ER, PgR and HER2/neu. Correlation of biomarker expression with traditional prognostic factors, serum biochemistry (notably insulin) and clinical outcome was assessed. IR was strongly positive (Allred score = 8) in 54% of tumors. High IR expression significantly correlated with favorable prognostic markers (low tumor grade, lymph node negativity and progesterone receptor positivity) but not with fasting levels of circulating insulin. At a median follow-up of 9.1 years, high vs. low IR expression (an Allred score of 8 vs. 0-7) was associated with statistically significant improved distant disease-free survival (multivariate hazard ratio (HR) = 0.4; P = 0.027) and overall survival (multivariate HR = 0.26; P = 0.005). IR is highly expressed in the majority of early stage breast cancers but this expression is not clearly down-regulated in the presence of high insulin levels. Furthermore, high expression of IR is independently and significantly associated with more favorable clinical outcomes. Follow-up intervention research is recommended.

[1]  R. Vigneri,et al.  High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells. , 1992, The Journal of clinical investigation.

[2]  P. Richardson,et al.  Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. , 2006, Journal of Clinical Oncology.

[3]  M. Railo,et al.  The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients. , 1994, Acta oncologica.

[4]  A. Scheen,et al.  Insulin action in man. , 1996, Diabetes & metabolism.

[5]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[6]  Robert E. Jones,et al.  Regulation of Sex Hormone Binding Globulin (SHBG) production in hep G2 cells by insulin , 1988, Steroids.

[7]  D. Yee,et al.  Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. , 2006, Cancer research.

[8]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[10]  C. Osborne,et al.  Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. , 1989, Cancer research.

[11]  R. Brand,et al.  Elevated insulin receptor content in human breast cancer. , 1990, The Journal of clinical investigation.

[12]  A. A. Hart,et al.  Insulin resistance and breast‐cancer risk , 1992, International journal of cancer.

[13]  B. Hoffman,et al.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Berrino,et al.  Metabolic syndrome as a prognostic factor for breast cancer recurrences , 2006, International journal of cancer.

[15]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[16]  G M Clark,et al.  Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. , 1993, Cancer research.

[17]  A. Kissebah,et al.  The relationship of insulin to sex hormone-binding globulin: role of adiposity. , 1989, Fertility and sterility.

[18]  E. Ben-hur,et al.  Hyperinsulinemia in colon, stomach and breast cancer patients. , 1996, Cancer letters.

[19]  A. Costantino,et al.  Insulin Receptors in Breast Cancer , 1996, Annals of the New York Academy of Sciences.

[20]  E. Froesch,et al.  Actions of insulin-like growth factors. , 1985, Annual review of physiology.

[21]  R Beuscart,et al.  Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. , 1990, Cancer research.

[22]  A. Belfiore,et al.  Insulin receptors in breast cancer: Biological and clinical role , 1996, Journal of endocrinological investigation.

[23]  M. Mathieu,et al.  Insulin receptor expression and clinical outcome in node-negative breast cancer. , 1997, Proceedings of the Association of American Physicians.

[24]  C. Redmond,et al.  Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.

[25]  M. Rechler,et al.  The nature and regulation of the receptors for insulin-like growth factors. , 1985, Annual review of physiology.

[26]  A. Costantino,et al.  Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells , 1999, Molecular and Cellular Biology.

[27]  Ash A. Alizadeh,et al.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. , 2002, The American journal of pathology.

[28]  E. Tsyrlina,et al.  Comparative study of blood insulin levels in breast and endometrial cancer patients. , 1997, Neoplasma.

[29]  J. Foekens,et al.  Insulin‐like growth factor‐1 receptors and insulin‐like growth factor‐1‐like activity in human primary breast cancer , 1989, Cancer.

[30]  K J Cullen,et al.  Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells , 1995, Journal of cellular physiology.

[31]  I. G. Fantus,et al.  Insulin and related factors in premenopausal breast cancer risk , 2004, Breast Cancer Research and Treatment.

[32]  W. Anderson,et al.  Insulin promotes the growth of F9 embryonal carcinoma cells apparently by acting through its own receptor. , 1982, Biochemical and biophysical research communications.

[33]  H. Adlercreutz.  Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. , 1990, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[34]  D. C. Whitelaw,et al.  Insulin Resistance , 1998, Annals of clinical biochemistry.

[35]  I. Andrulis,et al.  Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. , 2001, American journal of clinical pathology.

[36]  S. Sheps,et al.  Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  H. Huynh,et al.  Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. , 1996, Cancer research.

[38]  F. Frasca,et al.  Insulin‐stimulated cell growth in insulin receptor substrate‐1–deficient ZR‐75‐1 cells is mediated by a phosphatidylinositol‐3‐kinase–independent pathway , 1998, Journal of cellular biochemistry.

[39]  A. Lupulescu.  Effect of prolonged insulin treatment on carcinoma formation in mice. , 1985, Cancer research.